ReviewOncoTargets and therapy2021
Current Perspectives and Novel Strategies of
Review in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Objective response to immune checkpoint inhibitor therapy inFrontiers in medicine · 2023Pooled it
- Primary malignant melanoma with pseudovascular morphology: a diagnostic pitfall.Dermatology reports · 2026Article
- Targeting ABL kinases overcomes melanoma immune evasion following resistance to MAPK inhibition.Nature communications · 2026Article
- MAPK Inhibitor-Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities.Cancer science · 2026Review
- Review
- Article
- Somatic gene variation profiles in geriatric and adult malignant melanoma patients.Frontiers in oncology · 2025Article
- Primary Malignant Melanoma of the Sphenoid Sinus as a Crucial Differential Diagnosis of Skull Base Tumors: A Case Report.NMC case report journal · 2025Article
- Tunlametinib: First Approval.Drugs · 2024Review
- The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers.Cancer discovery · 2024Article
- STK19 is a DNA/RNA-binding protein critical for DNA damage repair and cell proliferation.The Journal of cell biology · 2024Article
- Article
- Article
- Spontaneous rupture of a solitary oligometastatic hepatic melanoma.BMJ case reports · 2023Article
- ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization.Cancers · 2023Article
- Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients.Journal of cancer research and clinical oncology · 2023Article
- Targeted Therapy for Melanomas Without BRAF V600 Mutation.Current oncology reports · 2022Review
- Novel Biomarkers and Therapeutic Targets for Melanoma.International journal of molecular sciences · 2022Review
- Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets.Journal of personalized medicine · 2022Review
- MALAT1 as master regulator of biomarkers predictive of pan-cancer multi-drug resistance in the context of recalcitrant NRAS signaling pathway identified using systems-oriented approach.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is the deadliest cutaneous cancer. Activating mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.